Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 15/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100062 | 0.89 | SLC16A1 (0.51) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL5138945 | 0.89 | SLC16A1 (0.56) | SLC16A1CYP2C9CYP3A4SLC16A7ALDH1A1 | |
| SCHEMBL5100179 | 0.80 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL5097869 | 0.79 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4SLC16A7ALDH1A1 | |
| SCHEMBL5096933 | 0.79 | SLC16A1 (0.49) | SLC16A1RAB9AALDH1A1LMNAMEN1 | |
| SCHEMBL3828116 | 0.78 | SLC16A1 (0.62) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL3828070 | 0.77 | SLC16A1 (0.72) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL5094497 | 0.77 | SLC16A1 (0.61) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL5094503 | 0.77 | SLC16A1 (0.61) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL3826879 | 0.77 | SLC16A1 (0.60) | SLC16A1CYP2C9CYP3A4SLC16A7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214579-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| EP-1587812-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2006-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214579-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | TPMT, TYMP, TYMS | SLC16A1 3968/4885CYP2C9 419/4885CYP3A4 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.